Brimonidine Tartrate + Timolol Maleate: Brands, Price & Uses in Bangladesh

Brimonidine Tartrate + Timolol Maleate ophthalmic solution is a fixed-dose combination eye drop indicated for the reduction ofelevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Established / FDA-approved use

• Reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocularhypertension who require adjunctive or replacement therapy because IOP is not adequatelycontrolled on a single topical agent.

Adjunct / combination-therapy use

• Brimonidine Tartrate + Timolol Maleate is intended to be used as adjunctive therapy in patients whose intraocular pressure isinsufficiently controlled with a beta-blocker or alpha-2 agonist alone, or as a replacement forconcurrent administration of the individual components (a topical alpha-2 agonist and a topicalbeta-blocker).

Note: Brimonidine Tartrate + Timolol Maleate is not intended for use as first-line, single-agent therapy in patientswho have not previously been treated with a topical anti-glaucoma agent; it is formulated forpatients who need the combined effect of both active ingredients.

Adults

Pediatric patients

Brimonidine Tartrate + Timolol Maleate is contraindicated in neonates and infants under 2 years of age. Use in children 2 years andolder should be individualized and closely supervised by a physician; seeUse in Special Populations for details.

Renal or hepatic impairment

Brimonidine Tartrate + Timolol Maleate has not been formally studied in patients with renal or hepatic impairment; no specificdose adjustment has been established. Use with caution and under medical supervision in suchpatients, since systemic absorption of both components occurs with topical use.

Administration technique

• For ophthalmic (eye drop) use only; not for injection or oral use.
• Wash hands before use and avoid letting the dropper tip touch the eye or any other surface, toprevent contamination.
• If using other topical ophthalmic products, space administration at least 5 minutes apart fromBrimonidine Tartrate + Timolol Maleate.
• Contact lenses should be removed before instilling Brimonidine Tartrate + Timolol Maleate and may be reinserted 15 minutes afteradministration, since the solution contains benzalkonium chloride, which can be absorbed by softcontact lenses.
• Do not change the dose or frequency without consulting a physician.

The following adverse effects have been reported with Brimonidine Tartrate + Timolol Maleate:

Common (ocular)

• Allergic conjunctivitis, conjunctival hyperemia (redness), conjunctival follicles
• Eye pruritus (itching), burning, and stinging on instillation
• Eye irritation, ocular allergic reaction, and blurred vision

Less common (systemic)

• Asthenia (weakness/fatigue), somnolence (drowsiness)
• Headache, dizziness
• Dry mouth
• Blepharitis, corneal erosion
• Depression
• Hypertension

Serious (uncommon but clinically important)

• Bradycardia, arrhythmia, cardiac arrest, or worsening of heart failure (timolol component;systemic beta-blocker effect)
• Bronchospasm or dyspnea, particularly in patients with reactive airway disease
• Hypotension
• Syncope

In young children who have been exposed to the brimonidine component, postmarketing reportsdescribe serious CNS depression, including apnea, bradycardia, hypotension, hypothermia, coma, andrespiratory depression; see Contraindications.

Patients should seek prompt medical attention if they experience difficulty breathing, chestpain, an irregular or very slow heartbeat, fainting, or a severe allergic reaction while usingBrimonidine Tartrate + Timolol Maleate.